Business segment information (Tables)

3 Months Ended

Mar. 31, 2014

Schedule of External Net Sales by SBU Reporting Segment

The table below presents external net sales by SBU reporting segment (amounts reported for prior periods have been reclassified to conform to our new segment reporting structure). Net sales include product sales and marketing service fees. Marketing service fees, which are recorded on a net basis, are comprised of fees earned for the marketing of Trinity Evolution^®, Trinity ELITE^® and Versashield™ in our Biologics segment.


	External Net Sales by SBU
	Three Months Ended March 31,
(U.S. Dollars, in thousands)	2014		2013		Reported Decline			Constant Currency Decline
	(Restated)		(Restated)		(Restated)			(Restated)
BioStim	$	37,137	$	37,226		—			—
Biologics		13,010		13,360		(3	)%		(3	)%
Extremity Fixation		27,066		26,197		3	%		4	%
Spine Fixation		22,801		25,496		(11	)%		(11	)%

Total Net Sales	$	100,014	$	102,279		(2	)%		(2	)%

Summary of Net Margin, Defined as Gross Profit Less Sales and Marketing Expenses from Continuing Operations by SBU Reporting Segment

The table below presents net margin, defined as gross profit less sales and marketing expenses, from continuing operations by SBU reporting segment:


Net margin by SBU	Three Months Ended March 31,
(U.S. Dollars, in thousands)	2014			2013
	(Restated)			(Restated)
Net margin:
BioStim	$	15,020		$	17,183
Biologics		6,502			6,018
Extremity Fixation		6,933			5,642
Spine Fixation		4,059			2,176
Corporate		(444	)		(425	)

Total net margin		32,070			30,594

General and administrative		17,276			18,241
Research and development		5,933			5,741
Amortization of intangible assets		584			544
Costs related to the accounting review and restatement		8,306			—

Operating (loss) income	$	(29	)	$	6,068